|
1
|
Huff LM, Lee JS, Robey RW and Fojo T:
Characterization of gene rearrangements leading to activation of
MDR-1. J Biol Chem. 281:36501–36509. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Sinha BK, Kumar A, Bhattacharjee S, Espey
MG and Mason RP: Effect of nitric oxide on the anticancer activity
of the topoisomerase-active drugs etoposide and adriamycin in human
melanoma cells. J Pharmacol Exp Ther. 347:607–614. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Zhu CY, Lv YP, Yan DF and Gao FL:
Knockdown of MDR1 increases the sensitivity to adriamycin in drug
resistant gastric cancer cells. Asian Pac J Cancer Prev.
14:6757–6760. 2013. View Article : Google Scholar
|
|
4
|
Deng S, Yan T, Jendrny C, Nemecek A,
Vincetic M, Gödtel-Armbrust U and Wojnowski L: Dexrazoxane may
prevent doxorubicin-induced DNA damage via depleting both
topoisomerase II isoforms. BMC Cancer. 14:8422014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Miura JT, Johnston FM, Thomas J, George B,
Eastwood D, Tsai S, Christians KK, Turaga KK and Gamblin TC:
Molecular profiling in gastric cancer: examining potential targets
for chemotherapy. J Surg Oncol. 110:302–306. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Smith NA, Byl JA, Mercer SL, Deweese JE
and Osheroff N: Etoposide quinone is a covalent poison of human
topoisomerase IIβ. Biochemistry. 53:3229–3236. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Pennock GD, Dalton WS, Roeske WR, et al:
Systemic toxic effects associated with high-dose verapamil infusion
and chemotherapy administration. J Natl Cancer Inst. 83:105–110.
1991. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hartmann JT and Lipp HP: Camptothecin and
podophyllotoxin derivatives: inhibitors of topoisomerase I and II -
mechanisms of action, pharmacokinetics and toxicity profile. Drug
Saf. 29:209–230. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Bender RP, Jablonksy MJ, Shadid M, et al:
Substituents on etoposide that interact with human topoisomerase
IIalpha in the binary enzyme-drug complex: contributions to
etoposide binding and activity. Biochemistry. 47:4501–4509. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Holden JA: DNA topoisomerases as
anticancer drug targets: from the laboratory to the clinic. Curr
Med Chem Anticancer Agents. 1:1–25. 2001. View Article : Google Scholar
|
|
11
|
Osheroff N: Effect of antineoplastic
agents on the DNA cleavage/religation reaction of eukaryotic
topoisomerase II: inhibition of DNA religation by etoposide.
Biochemistry. 28:6157–6160. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Robinson MJ and Osheroff N: Effects of
antineoplastic drugs on the post-strand-passage DNA
cleavage/religation equilibrium of topoisomerase II. Biochemistry.
30:1807–1813. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Chen Y, Lin TY, Chen JC, Yang HZ and Tseng
SH: GL331, a topoisomerase II inhibitor, induces radiosensitization
of human glioma cells. Anticancer Res. 26:2149–2156.
2006.PubMed/NCBI
|
|
14
|
Whang PJ and Huang TS: New trials of
GL331, a novel topoisomerase II inhibitor, in treatment of solid
tumors. J Intern Med Taiwan. 8:6–11. 1997.
|
|
15
|
Zhang YL, Tropsha A, McPhail AT and Lee
KH: Antitumor agents. 152. In vitro inhibitory activity of
etoposide derivative NPF against human tumor cell lines and a study
of its conformation by X-ray crystallography, molecular modeling,
and NMR spectroscopy. J Med Chem. 37:1460–1464. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Liu YQ, Tian J, Qian K, Zhao XB,
Morris-Natschke SL, Yang L, Nan X, Tian X and Lee KH: Recent
progress on C-4-modified podophyllotoxin analogs as potent
antitumor agents. Med Res Rev. 35:1–62. 2015. View Article : Google Scholar
|
|
17
|
Chen H, Bi W, Cao B, et al: A novel
podophyllotoxin derivative (YB-1EPN) induces apoptosis and
down-regulates express of P-glycoprotein in multidrug resistance
cell line KBV200. Eur J Pharmacol. 627:69–74. 2010. View Article : Google Scholar
|
|
18
|
Skehan P, Storeng R, Scudiero D, et al:
New colorimetric cytotoxicity assay for anticancer-drug screening.
J Natl Cancer Inst. 82:1107–1112. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Sullivan DM, Glisson BS, Hodges PK,
Smallwood-Kentro S and Ross WE: Proliferation dependence of
topoisomerase II mediated drug action. Biochemistry. 25:2248–2256.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Lemke K, Poindessous V, Skladanowski A and
Larsen AK: The antitumor triazoloacridone C-1305 is a topoisomerase
II poison with unusual properties. Mol Pharmacol. 66:1035–1042.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Li CH, Chen PY, Chang UM, et al: Ganoderic
acid X, a lanostanoid triterpene, inhibits topoisomerases and
induces apoptosis of cancer cells. Life Sci. 77:252–265. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Nooter K and Stoter G: Molecular
mechanisms of multidrug resistance in cancer chemotherapy. Pathol
Res Pract. 192:768–780. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kellner U, Sehested M, Jensen PB, Gieseler
F and Rudolph P: Culprit and victim - DNA topoisomerase II. Lancet
Oncol. 3:235–243. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Kimura K, Saijo M, Ui M and Enomoto T:
Growth state- and cell cycle-dependent fluctuation in the
expression of two forms of DNA topoisomerase II and possible
specific modification of the higher molecular weight form in the M
phase. J Biol Chem. 269:1173–1176. 1994.PubMed/NCBI
|
|
25
|
Chen W, Qiu J and Shen YM: Topoisomerase
IIα, rather than IIβ, is a promising target in development of
anti-cancer drugs. Drug Discov Ther. 6:230–237. 2012.PubMed/NCBI
|
|
26
|
Dingemans AM, Pinedo HM and Giaccone G:
Clinical resistance to topoisomerase-targeted drugs. Biochim
Biophys Acta. 1400:275–288. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Priel E, Aboud M, Feigelman H and Segal S:
Topoisomerase-II activity in human leukemic and lymphoblastoid
cells. Biochem Biophys Res Commun. 130:325–332. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Engstrøm MJ, Ytterhus B, Vatten LJ, Opdahl
S and Bofin AM: TOP2A gene copy number change in breast cancer. J
Clin Pathol. 67:420–425. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Pendleton M, Lindsey RH Jr, Felix CA,
Grimwade D and Osheroff N: Topoisomerase II and leukemia. Ann NY
Acad Sci. 1310:98–110. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pourpak A, Landowski TH and Dorr RT:
Ethonafide-induced cytotoxicity is mediated by topoisomerase II
inhibition in prostate cancer cells. J Pharmacol Exp Ther.
321:1109–1117. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Liu Y, Gao F, Jiang H, et al: Induction of
DNA damage and ATF3 by retigeric acid B, a novel topoisomerase II
inhibitor, promotes apoptosis in prostate cancer cells. Cancer
Lett. 337:66–76. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Nateewattana J, Dutta S, Reabroi S, et al:
Induction of apoptosis in cholangiocarcinoma by an andrographolide
analogue is mediated through topoisomerase II alpha inhibition. Eur
J Pharmacol. 723:148–155. 2014. View Article : Google Scholar
|
|
33
|
Zhang X, Bao B, Yu X, et al: The discovery
and optimization of novel dual inhibitors of topoisomerase II and
histone deacetylase. Bioorg Med Chem. 21:6981–6995. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bau JT, Kang Z, Austin CA and Kurz EU:
Salicylate, a catalytic inhibitor of topoisomerase II, inhibits DNA
cleavage and is selective for the α isoform. Mol Pharmacol.
85:198–207. 2014. View Article : Google Scholar
|
|
35
|
Chen H, Wang J, Zhang J, et al: L1EPO, a
novel podophyllotoxin derivative overcomes P-glycoprotein-mediated
multidrug resistance in K562/A02 cell line. Biol Pharm Bull.
32:609–613. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xu D, Cao J, Qian S, et al: 5k, a novel
β-O-demethyl-epipodophyllotoxin analogue, inhibits the
proliferation of cancer cells in vitro and in vivo via the
induction of G2 arrest and apoptosis. Invest New Drugs. 29:786–799.
2011. View Article : Google Scholar
|
